Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.

Employees

Sector

Biotechnology & Medical Research

Calendar

01/08 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
09/25/09	1.130 $	+7.62%	60,43,827
08/25/08	1.050 $	+8.25%	51,42,773
07/25/07	0.9700 $	+1.36%	46,18,132
03/25/03	0.9570 $	+3.30%	32,76,742
02/25/02	0.9264 $	+0.25%	34,74,814

Delayed Quote Nasdaq, July 10, 2025 at 01:30 am IST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.130USD

Average target price

6.500USD

Spread / Average Target

+475.22%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 01:30:00 10/07/2025 am IST			5-day change	1st Jan Change
1.130 ^USD	+7.62%		+22.28%	+40.37%

23/06	Carisma Therapeutics to Merge With OrthoCellix in All-Stock Transaction	MT
16/06	Ocugen Gets FDA Clearance to Start Phase 2/3 Stargardt Disease Trial	MT

Capitalization	33Cr 28Cr 26Cr 24Cr 45Cr 2.83TCr 51Cr 314.4Cr 119.63Cr 1.32TCr 123.77Cr 121.21Cr 4.84TCr	P/E ratio 2025 *	-5.06x	P/E ratio 2026 *	-5.02x
Enterprise value	33Cr 28Cr 26Cr 24Cr 45Cr 2.83TCr 51Cr 314.4Cr 119.63Cr 1.32TCr 123.77Cr 121.21Cr 4.84TCr	EV / Sales 2025 *	131x	EV / Sales 2026 *	203x
Free-Float	98.55%	Yield 2025 *	-	Yield 2026 *	-

Carisma Therapeutics to Merge With OrthoCellix in All-Stock Transaction	23/06	MT
Ocugen Gets FDA Clearance to Start Phase 2/3 Stargardt Disease Trial	16/06	MT
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of Ocu410st	16/06	CI
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of Ocu400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea	05/06	CI
Ocugen Signs Deal for Korean Rights to Gene Therapy OCU400	05/06	MT
Ocugen, Inc. Announces Signing Of Binding Term Sheet For The License Of Ocu400 Modifier Gene Therapy For Retinitis Pigmentosa In Korea	05/06	RE
Ocugen Gets FDA Rare Pediatric Disease Label for OCU410ST	27/05	MT
Ocugen's Retina Gene Therapy Drug Gets Rare Disease Designation From FDA	27/05	DJ
Ocugen Announces Rare Pediatric Disease Designation Granted For Ocu410st--Modifier Gene Therapy For The Treatment Of Stargardt Disease	27/05	RE
Ocugen, Inc. Announces Rare Pediatric Disease Designation Granted for OC410ST--Modifier Gene Therapy for the Treatment of Stargardt Disease	27/05	CI
Ocugen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	09/05	CI
Tranche Update on Ocugen, Inc.'s Equity Buyback Plan announced on October 9, 2019.	09/05	CI
Ocugen, Inc., Q1 2025 Earnings Call, May 09, 2025	09/05

Chardan Capital Adjusts Ocugen Price Target to $7 From $6, Maintains Buy Rating	06/03	MT
Chardan Adjusts Price Target on Ocugen to $5 From $4, Maintains Buy Rating	22/24/22	MT
Chardan Raises Price Target on Ocugen to $5 From $4, Keeps Buy Rating	22/24/22	MT
HC Wainwright Adjusts Price Target on Ocugen to $7 From $5, Maintains Buy Rating	24/24/24	MT
Cantor Fitzgerald Adjusts Ocugen's Price Target to $2 From $2.50, Keeps Overweight Rating	31/23/31	MT

Ocugen, Inc. Share Price

Equities

OCGN

US67577C1053

Biotechnology & Medical Research

Valuation: Ocugen, Inc.

Chart: Ocugen, Inc.

Latest news: Ocugen, Inc.

Last Transcript: Ocugen, Inc.

Analysts' recommendations: Ocugen, Inc.

Press Releases: Ocugen, Inc.

News in other languages: Ocugen, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Ocugen, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases	23/06	GL
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease	16/06	GL
Ocugen To Present at BIO International Convention 2025	11/06	GL
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea	05/06	GL
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease	27/05	GL

MÄRKTE USA/Erleichterungsrally - VMware mit 25%-Kurssprung	24/22/24
MÄRKTE USA/Sehr fest - Anleger greifen nach Durststrecke wieder zu	23/22/23
UPDATE/MÄRKTE USA/Fester - Präsident Biden sorgt für Hoffnungsschimmer	23/22/23
MÄRKTE USA/Fester - Präsident Biden sorgt für Hoffnungsschimmer	23/22/23
MÄRKTE USA/Fester erwartet - Biden weckt China-Fantasie	23/22/23

1 day	+7.62%
1 week	+22.28%
Current month	+16.45%
1 month	+6.60%
3 months	+93.89%
6 months	+36.00%
Current year	+40.37%

1 week	0.91	1.13
1 month	0.9	1.29
Current year	0.52	1.29
1 year	0.52	1.98
3 years	0.34	3.07
5 years	0.18	18.77
10 years	0.17	18.77

Manager	Title	Age	Since
Shankar Musunuri CEO	Chief Executive Officer	61	27/09/2019
Ramesh Ramachandran DFI	Director of Finance/CFO	56	14/11/2024
Jesse Simmers CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
C. Satish Chandran BRD	Director/Board Member	69	05/06/2025
Shankar Musunuri CHM	Chairman	61	27/09/2019
Blaise Coleman BRD	Director/Board Member	51	05/06/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
OCUGEN, INC.	+7.62%	+22.28%	-35.24%	-63.55%	31Cr
LONZA GROUP AG	+1.26%	-0.25%	+11.94%	-0.60%	4.92TCr
BEONE MEDICINES LTD.	+4.59%	+4.30%	+77.13%	+35.47%	2.9TCr
IQVIA HOLDINGS INC.	-1.49%	-0.36%	-22.46%	-26.13%	2.85TCr
CELLTRION, INC.	+0.34%	+9.79%	+4.85%	+9.59%	2.83TCr
EUROFINS SCIENTIFIC SE	+0.03%	-1.78%	+27.70%	-23.15%	1.25TCr
ICON PUBLIC LIMITED COMPANY	-0.69%	+1.11%	-53.09%	-30.93%	1.2TCr
QIAGEN N.V.	+0.23%	-0.52%	+15.87%	-6.36%	1.04TCr
ASCENDIS PHARMA A/S	+4.48%	+2.16%	+28.76%	+87.70%	1.02TCr
TEMPUS AI, INC.	-0.17%	-1.74%	+75.93%	-	1.01TCr
Average	+1.68%	+0.82%	+13.14%	-2.00%	1.9TCr
Weighted average by Cap.	+1.10%	-0.55%	+17.03%	+3.72%

	2025 *	2026 *
Net sales	25.16L 21.49L 20.02L 18.52L 34.47L 22Cr 38.53L 2.4Cr 91.19L 10Cr 94.35L 92.4L 37Cr	16.25L 13.88L 12.94L 11.96L 22.27L 14Cr 24.89L 1.55Cr 58.91L 6.51Cr 60.95L 59.69L 24Cr
Net income	-6.39Cr -5.46Cr -5.09Cr -4.7Cr -8.75Cr -547.63Cr -9.79Cr -61Cr -23Cr -255.85Cr -24Cr -23Cr -936.12Cr	-7.25Cr -6.19Cr -5.77Cr -5.34Cr -9.93Cr -621.29Cr -11Cr -69Cr -26Cr -290.26Cr -27Cr -27Cr -1.06TCr
Net Debt	-	-